Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®
Source:HAN ; 331
Corporate Authors:Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; Tennessee. Department of Public Health.
Series:HAN ; 331
Description:October 26, 2012, 18:00 ET (6:00 PM ET)
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing.
This HAN notice provides information on the following:
• Status of the investigation
• Background on T T P and Opana ER®
• Case definition
Supporting Files:No Additional Files
You May Also Like: